Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections
Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections
复制标题
DOI：
10.1136/bjophthalmol-2018-312649
复制
发表时间：
2019-08-01
影响因子：
4.1
通讯作者：
Galor, Anat
中科院分区：
文献类型：
--
作者：
Diel, Ryan J.;Hwang, Jodi;Galor, Anat
背景 评估 A 型肉毒毒素 (BoNT-A) 在减少慢性偏头痛患者畏光和干眼症状方面的功效。此外，我们的目的是评估泪膜体积作为这些患者症状的潜在因素。方法 回顾性分析 2017 年 8 月 23 日至 2017 年 12 月 13 日期间在迈阿密退伍军人事务医疗中心神经毒素诊所接受 BoNT-A 治疗慢性偏头痛的 76 例患者。通过图表审查查询人口统计数据和所有合并症。进行标准化验证的调查来评估 BoNT-A 注射前后的症状。使用酚红线（PRT）测试获得注射前泪液体积。结果 注射前偏头痛、畏光和干眼症状评分均显着相关，p = 6)，干眼症状更严重的个体更有可能得到改善，OR 1.27，95% CI 1.06 至 1.51，p结论 BoNT-A 显着改善了正在接受偏头痛治疗的患者的畏光症状，并且还改善了基线时症状严重的患者的干眼症状，与基线泪膜量无关。这些改善可能是由于共享三叉神经通路的调节。
Background To evaluate the efficacy of botulinum toxin A (BoNT-A) in reducing photophobia and dry eye symptoms in individuals with chronic migraine. Additionally, we aimed to evaluate tear film volume as a potential contributor to symptoms in these patients. Methods Retrospective review of 76 patients who received BoNT-A for chronic migraine between 23 August 2017 and 13 December 2017 at the Miami Veterans Affairs Medical Center Neurotoxin Clinic. Demographic data and all comorbidities were queried via chart review. Standardised validated surveys were administered to assess symptoms prior to and after BoNT-A injection. Preinjection tear volumes were obtained using the phenol red thread (PRT) test. Results Preinjection migraine, photophobia and dry eye symptom scores were all significantly correlated, p= 6), individuals with more severe dry eye symptoms were more likely improve, OR 1.27, 95% CI 1.06 to 1.51, pConclusions BoNT-A significantly improved photophobia in patients being treated for migraine and also improved dry eye symptoms in patients with severe symptoms at baseline, independent of baseline tear film volume. These improvements may be due to modulation of shared trigeminal neural pathways.